Oxbow Advisors LLC Cuts Position in Pfizer (PFE)

Oxbow Advisors LLC reduced its stake in Pfizer (NYSE:PFE) by 1.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 242,451 shares of the biopharmaceutical company’s stock after selling 2,606 shares during the quarter. Pfizer accounts for 1.6% of Oxbow Advisors LLC’s portfolio, making the stock its 12th largest position. Oxbow Advisors LLC’s holdings in Pfizer were worth $8,782,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Mckinley Capital Management LLC Delaware acquired a new stake in Pfizer in the 2nd quarter valued at $103,000. Americafirst Capital Management LLC acquired a new stake in Pfizer in the 3rd quarter valued at $127,000. Lipe & Dalton increased its stake in Pfizer by 6.9% in the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 300 shares during the last quarter. Legacy Advisors LLC acquired a new stake in Pfizer in the 3rd quarter valued at $164,000. Finally, Oak Point Wealth Management acquired a new stake in Pfizer in the 4th quarter valued at $165,000. 71.20% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Shares of PFE opened at $35.17 on Friday. Pfizer has a 52 week low of $31.67 and a 52 week high of $39.43. The stock has a market capitalization of $215,077.02, a P/E ratio of 13.27, a P/E/G ratio of 1.80 and a beta of 0.90. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The business had revenue of $13.70 billion for the quarter, compared to analyst estimates of $13.67 billion. During the same quarter in the prior year, the business earned $0.47 EPS. Pfizer’s quarterly revenue was up .6% on a year-over-year basis. equities analysts expect that Pfizer will post 2.96 earnings per share for the current year.

Pfizer announced that its board has initiated a share buyback plan on Monday, December 18th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

PFE has been the topic of several recent research reports. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Friday, December 8th. Nord/LB reiterated a “neutral” rating on shares of Pfizer in a research note on Wednesday, December 27th. Morgan Stanley set a $41.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Friday, January 5th. Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price target on the stock in a research note on Monday, January 8th. Finally, Jefferies Group set a $40.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday, January 16th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company’s stock. Pfizer currently has an average rating of “Hold” and a consensus target price of $39.25.

In related news, insider Kirsten Lund-Jurgensen sold 9,510 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $37.19, for a total value of $353,676.90. Following the transaction, the insider now owns 36,959 shares in the company, valued at approximately $1,374,505.21. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Sally Susman sold 33,368 shares of the company’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $37.03, for a total transaction of $1,235,617.04. Following the completion of the transaction, the executive vice president now owns 191,505 shares in the company, valued at approximately $7,091,430.15. The disclosure for this sale can be found here. In the last quarter, insiders sold 248,037 shares of company stock worth $9,064,785. 0.06% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/oxbow-advisors-llc-cuts-position-in-pfizer-pfe.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply